Information Provided By: 
Fly News Breaks for August 13, 2019
CVSI
Aug 13, 2019 | 06:11 EDT
Piper Jaffray analyst Michael Lavery last night initiated coverage of CV Sciences with an Overweight rating and $5 price target. The analyst says CV Sciences is the second largest public U.S. CBD company by revenues, and he expects its distribution expansion to drive near-term sales growth. He considers science and regulation to be a core competency for CV Sciences, and also believes that clarity on FDA regulation for other products is a "looming positive catalyst." Lavery believes the U.S. CBD market could be an $8B-$15B market in five years.
News For CVSI From the Last 2 Days
CVSI
Apr 25, 2024 | 10:57 EDT
In this week's "Rising High," The Fly's recurring series focused on cannabis and psychedelic stock news, The Fly looks back on study dosing, a completed acquisition and a research partnership. ATAI ANNOUNCES DOSING... To see the rest of the story go to thefly.com. See Story Here
